Burden of varicella complications in secondary care, England, 2004 to 2017

被引:26
作者
Bernal, James Lopez [1 ]
Hobbelen, Peter [1 ,2 ]
Amirthalingam, Gayatri [1 ]
机构
[1] Publ Hlth England, Natl Infect Serv, Immunisat & Countermeasures Div, Colindale, England
[2] Wageningen Biovet Res, Dept Bacteriol & Epidemiol, Lelystad, Netherlands
来源
EUROSURVEILLANCE | 2019年 / 24卷 / 42期
关键词
HERPES-ZOSTER INCIDENCE; UNITED-STATES; VACCINATION; HOSPITALIZATIONS; SURVEILLANCE; INFECTIONS; CHILDREN; UK;
D O I
10.2807/1560-7917.ES.2019.24.42.1900233
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Strategies to control varicella vary across Europe. Evidence from established programmes has prompted the United Kingdom to re-evaluate the need for universal vaccination. The burden of complicated varicella is a key parameter in the cost-effectiveness analysis. Aim: Our objective was to estimate the burden of complicated varicella in England. Methods: This electronic health record surveillance study used data from all NHS hospitals in England to identify varicella admissions between 2004 and 2017. The incidence of pre-defined complications of varicella was estimated using ICD-10 codes. Inpatient costs were calculated based on the payment rules for providers of NHS services. Results: There were 61,024 admissions with varicella between 2004 and 2017 and 38.1% had a recognised varicella complication. Incidence of hospitalisation increased by 25% and the proportion with complicated varicella by 24% from 2004/05 to 2016/17. The most common complications were bacterial skin infections (11.25%), pneumonia (4.82%), febrile convulsions ( 3.39%) and encephalitis (2.44%). Complication rates were higher in older age groups and the type of complications more severe. Length of stay for complicated varicella was 3.1 times longer than for uncomplicated varicella and inpatient costs were 72% greater. Conclusion: Complicated varicella has a substantial health and economic burden. These data together with data on impact on quality of life are important in informing the cost-effectiveness analysis of universal varicella vaccination.
引用
收藏
页码:30 / 38
页数:9
相关论文
共 25 条
[1]  
Abdalrahman Bayad, 2015, JRSM Open, V6, p2054270414562984, DOI 10.1177/2054270414562984
[2]   Varicella paediatric hospitalisations in Belgium: a 1-year national survey [J].
Blumental, Sophie ;
Sabbe, Martine ;
Lepage, Philippe .
ARCHIVES OF DISEASE IN CHILDHOOD, 2016, 101 (01) :16-22
[3]   Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents [J].
Bonhoeffer, J ;
Baer, G ;
Muehleisen, B ;
Aebi, C ;
Nadal, D ;
Schaad, UB ;
Heininger, U .
EUROPEAN JOURNAL OF PEDIATRICS, 2005, 164 (06) :366-370
[4]   Varicella vaccination in England and Wales: cost-utility analysis [J].
Brisson, M ;
Edmunds, WJ .
ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (10) :862-869
[5]   Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox [J].
Brisson, M ;
Gay, NJ ;
Edmunds, WJ ;
Andrews, NJ .
VACCINE, 2002, 20 (19-20) :2500-2507
[6]   Severe complications of chickenpox in hospitalised children in the UK and Ireland [J].
Cameron, J. C. ;
Allan, G. ;
Johnston, F. ;
Finn, A. ;
Heath, P. T. ;
Booy, R. .
ARCHIVES OF DISEASE IN CHILDHOOD, 2007, 92 (12) :1062-1066
[7]   Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina [J].
Clements, DA ;
Zaref, JI ;
Bland, CL ;
Walter, EB ;
Coplan, PM .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2001, 155 (04) :455-461
[8]   Epidemiology of hospital admissions for paediatric varicella infections: a one-year prospective survey in the pre-vaccine era [J].
Dubos, F. ;
Grandbastien, B. ;
Hue, V. ;
Martinot, A. .
EPIDEMIOLOGY AND INFECTION, 2007, 135 (01) :131-138
[9]  
European Centre for Disease Prevention and Control (ECDC), VACC SCHED VACC SCHE
[10]   Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data [J].
Goldman, G. S. ;
King, P. G. .
VACCINE, 2013, 31 (13) :1680-1694